

Please See Comments Below

## Sequential Screen | Fβ Report

Physician ID #: 24328  
 Physician Tel #: (000) 000-0000  
 OB SPECIALISTS  
 100 ANYWHERE ST  
 MELVILLE, NY 11747

Patient Name: EXTREME, SEQUENTIAL

Client ID #:

Patient ID #: 17SE0099997	<u>2nd Trimester data</u>	<u>1st Trimester data</u>
Date of Birth: 12/03/86	Insulin Rx: No	CRL (mm): 58
Age at EDC: 30	Fam Hx ONTD: No	U/S Date: 02/14/17
Mat. Weight: 120 lbs	State: NY	GA @ U/S: 12w1d
Ethnicity: Afr. Amer./Carib.	Draw Date: 03/11/17	Draw Date: 02/14/17
Prev Chrom Hx: None	GA @ Draw: 15w5d	GA @ Draw: 12w1d
Multi. Preg: No	GA by: 1TCRL	Report Date:
Smoker: No	Date Received: 03/13/17	
	Report Date: 03/14/17	




**2nd Trimester**

Marker/Analyte	Value	MoM	%ile
AFP	9.3 (IU/ml)	0.25*	0.1
Free Beta hCG	9.61 (ng/ml)	0.70	30
uE3	<1.5 (nmol/L)	0.45*	0.5
Inhibin-A	204.35 (pg/ml)	1.08	50

**1st Trimester**

Marker/Analyte	Value	MoM/Delta	%ile
Free Beta hCG	22.01 (ng/ml)	0.24 MoM	0.5*
PAPP-A	1.64 (mIU/ml)	0.59 MoM	20
AFP	36.04 (IU/ml)	1.37 MoM	70
NT	2.2 (mm)	+0.7 Delta	75
Nasal Bone	Present	--	--

Sequential Risk Table	Cut-Off	Risk Before Screening	Risk After Screening	Result
Down Syndrome	1 in 300	1 in 691	1 in < 5	<b>INCREASED RISK</b>
Trisomy 18	1 in 150	1 in 2,029	1 in 37	<b>INCREASED RISK</b>
Total ONTDs/VWD	2 MoM	1 in 833	1 in 199,312	<b>WITHIN RANGE</b>
Open Spina Bifida	--	1 in 3,333	1 in > 250,000	---
Anencephaly	--	1 in 2,500	1 in > 250,000	---
Ventral Wall Defect	--	1 in 2,000	1 in > 250,000	---



**Recommendations:**

- Genetic counseling and offer of amniocentesis for diagnostic confirmation or noninvasive prenatal testing (NIPT).

**Comments:**

\* First trimester free beta hCG ≤ 1st percentile is associated with a 3.6 fold increase in risk of fetal loss before 24 weeks gestation and 2.7 fold increase in risk of low birth weight (< 10th percentile) (Dugoff L, et al. Obstet Gynecol. 2010; 115: 1052-61 and Krantz DA, et al. Am J Obstet Gynecol. 2004; 191: 1452-8.).

\* Maternal serum AFP ≤ 0.25 MoM is associated with a risk increase of 15 fold for spontaneous abortion, 2.2 fold for preterm birth, 4.0 fold for stillbirth, and 2.2 fold for macrosomia (Krause TG, et al. Obstet Gynecol. 2001; 97: 277-82 and Baschat AA, et al. Obstet Gynecol. 2002; 99: 531-6.).

\* uE3 ≤ 0.5 MoM is associated with a risk increase of 2 fold for low birth weight (< 5th percentile) and 7 fold for fetal loss (< 24 weeks) (Dugoff L, et al. Obstet Gynecol. 2005; 106: 260-267.).

Jonathan B. Carmichael, Ph.D  
 Laboratory Director,  
 Eurofins NTD, LLC

Terrence W. Hallahan, Ph.D  
 Laboratory Director,  
 Eurofins NTD, LLC

Physician ID #: 24328  
Physician Tel #: (000) 000-0000  
OB SPECIALISTS  
100 ANYWHERE ST  
MELVILLE, NY 11747

Patient Name: EXTREME, SEQUENTIAL

Client ID #:

Patient ID #: 17SE0099997

Date of Birth: 12/03/86

Age at EDC: 30

Mat. Weight: 120 lbs

Ethnicity: Afr. Amer./Carib.

Prev Chrom Hx: None

Multi. Preg: No

Smoker: No

2nd Trimester data

Insulin Rx: No

Fam Hx ONTD: No

State: NY

Draw Date: 03/11/17

GA @ Draw: 15w5d

GA by: 1TCRL

Date Received: 03/13/17

Report Date: 03/14/17

1st Trimester data

CRL (mm): 58

U/S Date: 02/14/17

GA @ U/S: 12w1d

Draw Date: 02/14/17

GA @ Draw: 12w1d

Report Date:

CAUTION: The test was developed and its performance characteristics determined by Eurofins NTD, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health. These results do not eliminate the possibility that this pregnancy may be associated with birth defects including open neural tube defects, ventral wall defects, Down syndrome, trisomy 18, or other disorders not detectable by this screening test. This report contains Protected Health Information. The recipient shall not disclose this information without the permission of the patient unless required to provide appropriate medical care. **Any recommendations or comments on specific analytes are provided as a courtesy to the ordering physician and do not constitute medical advice.**